These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 9196161

  • 1. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 2. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 3. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ.
    J Clin Oncol; 2002 Mar 01; 20(5):1361-7. PubMed ID: 11870180
    [Abstract] [Full Text] [Related]

  • 4. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 01; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 5. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 01; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T.
    Jpn J Clin Oncol; 1998 Aug 01; 28(8):497-501. PubMed ID: 9769784
    [Abstract] [Full Text] [Related]

  • 7. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul 01; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 8. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G, Milani A, Piva L, Faustini M, Spino E.
    Eur Urol; 1991 Jul 01; 20(2):89-92. PubMed ID: 1752280
    [Abstract] [Full Text] [Related]

  • 9. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct 01; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Oct 01; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 01; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y.
    J Clin Oncol; 1993 Mar 01; 11(3):408-14. PubMed ID: 7680373
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.
    Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L, EORTC Genito-Urinary Cancer Group.
    Eur J Cancer; 2006 Jan 01; 42(1):50-4. PubMed ID: 16330205
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.